| Trial ID: | L0099 |
| Source ID: | NCT01431521
|
| Associated Drug: |
MK-4074
|
| Title: |
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
|
| Acronym: |
--
|
| Status: |
Completed
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT01431521/results
|
| Conditions: |
Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: MK-4074 200 mg|Drug: Placebo for MK-4074|Drug: Pioglitazone hydrochloride 30 mg|Drug: Placebo for pioglitazone hydrochloride
|
| Outcome Measures: |
Percent Change From Baseline in Hepatic Fat|Number of Participants Experiencing One or More Adverse Events (AE)|Number of Participants Who Discontinued Study Drug Due to an AE|Percent Change From Baseline in Alanine Transaminase (ALT)|Percent Change From Baseline Aspartate Transaminase (AST)
|
| Sponsor/Collaborators: |
Merck Sharp & Dohme Corp.
|
| Gender: |
All
|
| Age: |
18 Years to 60 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
31
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
October 26, 2011
|
| Completion Date: |
October 1, 2012
|
| Results First Posted: |
March 25, 2016
|
| Last Update Posted: |
September 10, 2018
|
| Locations: |
--
|
| URL: |
https://ClinicalTrials.gov/show/NCT01431521
|
